Peter Alterman named COO of SAFE-BioPharma

Monday, August 13, 2012 03:13 PM

Peter Alterman, Ph.D., who held numerous senior information security positions within the U.S. federal government, has been named chief operating officer of SAFE-BioPharma Association, the strategic, non-profit collaboration responsible for the global SAFE-BioPharma digital identity and digital signature standard used in the life science and healthcare sectors.
 
Alterman recently retired after 33 years of government service where, most recently, he was senior advisor to the national program office of the National Strategy for Trusted Identities in Cyberspace (NSTIC), NIST. Before that he served as senior advisor to the NIH CIO for Strategic Initiatives, Assistant CIO for e-authentication at the National Institutes of Health and chair of the U.S. Federal PKI Policy Authority. His role in Internet technology started in 1989 as a member of the Federal Research Internet Coordinating Committee.
  
In addition to responsibilities for a variety of association management functions, Alterman will serve as SAFE-BioPharma’s primary liaison with the FDA and other global regulatory authorities and represent the association’s interests on global standards and policy bodies.

Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs